INCY
IncyteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
INCY vs peer average
61/100
INCY vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 3 · D 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
GMAB is the first available peer comparator.
Genmab is the closest peer in the supplied candidate set for oncology innovation and antibody-driven pipeline optionality. It is not a perfect commercial mix match, but it is a better comparator than broad healthcare tools or royalty names when judging whether investors pay for late-stage oncology execution.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
INCY
Incyte
GMAB
Genmab A/S
Grade
B
B
Momentum
46
28
Value
66
64
Sentiment
66
92
Setup Bias
Net Bullish
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs GMAB
INCY / GMAB
Grade Position
In line
INCY vs. peer average (B vs. C)
61/100
Momentum
46
INCYValue
66
INCYSentiment
66
GMABRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs INCY
GMAB is the first peer returned for this comparison set.